Table 1. Studies specifically addressing the impact of weight change during treatment in NSCLC patients.
| Reference | Patients (n) | Stage | WG patients, n (%) | Median OS, WG vs. WL | P value |
|---|---|---|---|---|---|
| Sher et al. (11) | 92 | IIIA/B | 51 (55.0) | 51.0 vs. 23.0 mo | 0.030 |
| Gielda et al. (12) | 54 | III–IV | 26 (48.1) | Not reached yet vs. 16.3 mo | 0.001 |
| Topkan et al. (10) | 425 | IIIB | 173 (40.7) | 27.3 vs. 17.8 mo | <0.001 |
| Patel et al. (4) | 2,301 | III–IV | 421 (18.3)* | 16.7 vs. 10.7 mo | 0.001 |
| 1,066 (46.3) | 15.2 vs. 8.6 mo | 0.001 |
*, patients with >5% WG. NSCLC, non-small cell lung cancer; WG, weight gain; OS, overall survival; WL, weight loss; mo, months.